We are live on ! Find out more
RXDX

Prometheus Biosciences, Inc. Common Stock
RXDX

Delisted

RXDX was delisted on the 15th of June, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Prometheus Biosciences, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $1.98M → $0 (-$1.98M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
–
Holders Change
-2
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$1.98M
2
FCA
FinTrust Capital Advisors
South Carolina
-$1.43K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
1
UBS AM
Illinois
– -$1.98M -18,448 Closed
FCA
2
FinTrust Capital Advisors
South Carolina
– -$1.43K -13 Closed

RXDX Hedge Fund Activity: Q3 2023 in Review

0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q3 2023, worth a combined $0 — down 100% from $1.98M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RXDX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was UBS AM, exiting entirely with an estimated $1.98M sold.

  • 0 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q3 2023, down from 2 in Q2 2023.
  • Funds reported $0 of Prometheus Biosciences, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of -2 holders.
  • The largest Prometheus Biosciences, Inc. Common Stock seller in Q3 2023 was UBS AM, an estimated $1.98M sold.

Based on aggregated 13F filings for Q3 2023.